Ipsen’s partner Exelixis announces clinical collaboration with Bristol Myers Squibb for late-stage combination trial in first-line renal cell carcinoma.

This article or press release has no online content. Please download the associated documents for more information.

A Life in a Day of an FOP person: from Empathy to Understanding…

Ipsen anti-corruption system certification renewed in 2022

A word from CEO David Loew

Ipsen becomes a founding sponsor of the second Biolabs innovation hub in Europe at Hopital Hotel Dieu, AP-HP

Choose your location: